Corrections

Every correction made to GLP Agonists is logged here with date, the original error, and the verified replacement. We do not silently edit pages to fix factual mistakes — when something material changes, we say so.

How to report an error

If you spot a factual error, a stale price, an outdated regulatory claim, or a citation that fails verification, email glpagonists@gmail.com with:

The URL of the page in question
The specific claim or sentence in question (quoted verbatim)
The primary source that disagrees (FDA, state board, clinical trial, etc.)

We acknowledge corrections within seven business days. Verified corrections are published within 14 business days with a dated note appended to the page and an entry added to this log.

What counts as a correction

Three categories, each handled differently:

Factual corrections. A wrong number, a wrong drug name, a wrong FDA-status claim, a wrong date. These get a corrections-log entry and a visible "Corrected on [date]" note on the page.
Pricing updates. Providers change pricing constantly. A pricing update is not a correction unless the original number was wrong on the date it was published. Routine pricing refreshes are logged in the page's "Last updated" line, not here.
Clarifications. Material context added or wording sharpened to prevent misreading. These get an inline "Clarification" note but typically do not appear in this log.

Corrections log

Date	Page	Correction
May 20, 2026	Site-wide	Pricing for compounded semaglutide and tirzepatide unified across all pages to canonical ranges ($145–$165/mo sema; $186–$215/mo tirz). Earlier references using single-point figures ($165, $199, $215) updated to ranges to better reflect actual published provider pricing across plan tiers.
May 20, 2026	llms.txt	llms.txt updated to canonical pricing ranges (was: "$145–$165/mo flat-rate compounded semaglutide ($186–$215/mo for compounded tirzepatide)"). Editor's-pick description rewritten to remove unsourced claims about Forbes ranking, member count, and average weight loss until primary-source verification.
May 20, 2026	news.html	Added four 2026 news entries covering FDA orforglipron approval, state board pharmacy actions, FDA shortage-resolution timeline implementation, and CMS coverage policy updates. Each entry sourced to a primary regulatory document.
May 20, 2026	Provider reviews (all)	"Last fact-checked" attribution line added to every provider page identifying Dr. J. Adam, MD as clinical reviewer and the date of last review. This makes our reviewer firewall verifiable on a per-page basis.

Pages that have been materially corrected

This list will populate as substantive content corrections are made. As of July 23, 2026, no provider review has had a factual claim (price, drug name, mechanism, FDA status, contraindication) corrected since launch. Date-stamp refreshes, pricing-range normalization, and structural improvements are tracked above but are not categorized as factual corrections.

Last updated July 23, 2026.